Ignite Creation Date:
2024-05-06 @ 12:29 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01586156
Status:
COMPLETED
Last Update Posted:
2018-12-05
First Post:
2012-04-23
Brief Title:
PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure Carvedilol
Sponsor:
The Cleveland Clinic
Organization:
The Cleveland Clinic
Study Overview
Official Title:
Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PAHTCH
Brief Summary:
Pulmonary arterial hypertension PAH is a progressive disease of the pulmonary vasculature leading to elevated pulmonary pressure and right ventricular RV dysfunction with heart failure Measures of RV function are better predictors of mortality and long term outcomes than pulmonary vascular resistance The interaction between RV function and the pulmonary circulation is not fully understood but increased after load appears insufficient to explain right heart failure Yet all approved PAH therapies target vasodilation of the pulmonary vasculature to lower pressures
Detailed Description:
Pulmonary arterial hypertension PAH is a serious condition characterized by endothelial dysfunction leading to pulmonary vascular constriction smooth muscle and endothelial proliferation and progressive right-sided heart failure The severity of pulmonary hypertension is mostly determined by the response of the right ventricle RV to the increased afterload or pulmonary pressures and RV failure is the leading cause of death in PAH Most accepted therapies for PAH have been aimed at vasodilation of the pulmonary vasculature and there has been little thought that PAH patients would benefit from traditional left heart failure treatments A cornerstone therapy in left heart failure is -adrenergic receptor blockade because of its ability to reverse cardiac remodeling and improve clinical outcomes despite decades of concern regarding its propensity to exacerbate heart failure It has been reported to reduce mortality by about 30 in patients and while the precise mechanisms that contribute to its beneficial effects remain to be elucidated there is evidence that patients with underlying contractile reserve ie via recruitment of viable myocardium with -adrenergic receptor stimulation may experience greater recovery of their cardiac function In a study using rats with pulmonary hypertension treated with blocker RV function improved and maladaptive myocardial remodeling was prevented
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL115008 | NIH | None | httpsreporternihgovquickSearchR01HL115008 |